Tirofiban-induced thrombocytopenia

References

• Huang J, Li X, Shi X, et al. Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting. J Hematol Oncol. 2019;12(1):1. doi: 10.1186/s13045-019-0709-6.
   PubMed Web of Science ®Google Scholar
• King S, Short M, Harmon C. Glycoprotein IIb/IIIa inhibitors: the resurgence of tirofiban. Vascul Pharmacol. 2016;78:10–11. doi: 10.1016/j.vph.2015.07.008.
   PubMed Web of Science ®Google Scholar
• Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol. 2003;41(1):26–32. doi: 10.1016/s0735-1097(02)02666-9.
   PubMed Web of Science ®Google Scholar
• Yang M, Huo X, Miao Z, et al. Platelet glycoprotein IIb/IIIa receptor inhibitor tirofiban in acute ischemic stroke. Drugs. 2019;79(5):515–529. doi: 10.1007/s40265-019-01078-0.
   PubMed Web of Science ®Google Scholar
• Siebler M, Hennerici MG, Schneider D, et al. Safety of tirofiban in acute ischemic stroke: the SaTIS trial. Stroke. 2011;42(9):2388–2392. doi: 10.1161/STROKEAHA.110.599662.
   PubMed Web of Science ®Google Scholar
• Huo, Xiaochuan, Wang, Anxin, Mo, Dapeng, et al., Safety and efficacy of tirofiban for acute ischemic stroke patients with large artery atherosclerosis stroke etiology undergoing endovascular therapy. Front Neurol. 2021;12:630301. doi: 10.3389/fneur.2021.630301.
   PubMed Web of Science ®Google Scholar
• McClellan KJ, Goa KL. Tirofiban. A review of its use in acute coronary syndromes. Drugs. 1998;56(6):1067–1080. doi: 10.2165/00003495-199856060-00017.
   PubMed Web of Science ®Google Scholar
• Yi Y-H, Yin W-J, Gu Z-C, et al. A simple clinical pre-procedure risk model for predicting thrombocytopenia associated with periprocedural use of tirofiban in patients undergoing percutaneous coronary intervention. Front Pharmacol. 2018;9:1456. doi: 10.3389/fphar.2018.01456.
   PubMed Web of Science ®Google Scholar
• Wessler JD, Giugliano RP. Risk of thrombocytopenia with glycoprotein IIb/IIIa inhibitors across drugs and patient populations: a meta-analysis of 29 large placebo-controlled randomized trials. Eur Heart J Cardiovasc Pharmacother. 2015;1(2):97–106. doi: 10.1093/ehjcvp/pvu008.
   PubMedGoogle Scholar
• Teke HÜ, Teke D. Profound thrombocytopenia related with tirofiban: will it be enough to only stop medicine? Platelets. 2013;24(4):335–337. doi: 10.3109/09537104.2012.696749.
   PubMed Web of Science ®Google Scholar
• Merlini PA, Rossi M, Menozzi A, et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation. 2004;109(18):2203–2206. doi: 10.1161/01.CIR.0000127867.41621.85.
   PubMed Web of Science ®Google Scholar
• Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344(25):1888–1894. doi: 10.1056/NEJM200106213442502.
   PubMed Web of Science ®Google Scholar
• The PRISM study investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338(21):1498–1505.
   PubMed Web of Science ®Google Scholar
• The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997;96(5):1445–1453. doi: 10.1161/01.CIR.96.5.1445.
   PubMed Web of Science ®Google Scholar
• Clofent-Sanchez G, Harizi H, Nurden A, et al. A case of profound and prolonged tirofiban-induced thrombocytopenia and its correction by intravenous immunoglobulin G. J Thromb Haemost. 2007;5(5):1068–1070. doi: 10.1111/j.1538-7836.2007.02440.x.
   PubMed Web of Science ®Google Scholar
• Bosco A, Kidson-Gerber G, Dunkley S. Delayed tirofiban-induced thrombocytopenia: two case reports. J Thromb Haemost. 2005;3(5):1109–1110. doi: 10.1111/j.1538-7836.2005.01296.x.
   PubMed Web of Science ®Google Scholar
• Velibey Y, Golcuk Y, Ekmekci A, et al. Tirofiban-induced acute profound thrombocytopenia: what is the optimal approach to treatment? Platelets. 2015;26(2):197–198. doi: 10.3109/09537104.2013.787406.
   PubMed Web of Science ®Google Scholar
• Bougie DW, Wilker PR, Wuitschick ED, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood. 2002;100(6):2071–2076. doi: 10.1182/blood.V100.6.2071.h81802002071_2071_2076.
   PubMed Web of Science ®Google Scholar
• Zhou X, Peng H, Yin Y, et al. Diffused alveolar hemorrhage: a rare and severe complication of tirofiban-induced thrombocytopenia. Int J Cardiol. 2016;206:93–94. doi: 10.1016/j.ijcard.2016.01.020.
   PubMed Web of Science ®Google Scholar
• Ibrahim T, El Karak F, Araji A, et al. Tirofiban-induced thrombocytopenia occurring with crohn’s disease. Case Rep Cardiol. 2016;2016:4605139. doi: 10.1155/2016/4605139.
   PubMedGoogle Scholar
• Vayne C, Guéry E-A, Rollin J, et al. Pathophysiology and diagnosis of Drug-Induced immune thrombocytopenia. JCM. 2020;9(7):2212. doi: 10.3390/jcm9072212.
   Google Scholar
• Hofer CK, Straumann E, Genoni M, et al. Profound drug-induced thrombocytopenia before urgent cardiopulmonary bypass✩. Interact Cardiovasc Thorac Surg. 2002;1(2):63–65. doi: 10.1016/s1569-9293(02)00016-6.
   PubMedGoogle Scholar
• Dunkley S, Lindeman R, Evans S, et al. Evidence of platelet activation due to tirofiban-dependent platelet antibodies: double trouble. J Thromb Haemost. 2003;1(10):2248–2250. doi: 10.1046/j.1538-7836.2003.00429.x.
   PubMed Web of Science ®Google Scholar
• Eryonucu B, Tuncer M, Erkoc R. Repetitive profound thrombocytopenia after treatment with tirofiban: a case report. Cardiovasc Drugs Ther. 2004;18(6):503–505. doi: 10.1007/s10557-004-6228-9.
   PubMed Web of Science ®Google Scholar
• Mulot A, Moulin F, Fohlen-Walter A, et al. Practical approach to the diagnosis and management of thrombocytopenia associated with tirofiban treatment. Am J Hematol. 2004;77(1):67–71. doi: 10.1002/ajh.20149.
   PubMed Web of Science ®Google Scholar
• Patel S, Patel M, Din I, et al. Profound thrombocytopenia associated with tirofiban: case report and review of literature. Angiology. 2005;56(3):351–355. doi: 10.1177/000331970505600319.
   PubMed Web of Science ®Google Scholar
• Tuhta AG, Yeşildağ O, Köprülü D. Tirofiban-associated acute thrombocytopenia. Acta Cardiol. 2006;61(5):577–579. doi: 10.2143/AC.61.5.2017776.
   PubMed Web of Science ®Google Scholar
• Demirkan B, Guray Y, Guray U, et al. Differential diagnosis and management of acute profound thrombocytopenia by tirofiban: a case report. J Thromb Thrombolysis. 2006;22(1):77–78. doi: 10.1007/s11239-006-7789-1.
   PubMed Web of Science ®Google Scholar
• Dorsch MP, Montague D, Rodgers JE, et al. Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia. Pharmacotherapy. 2006;26(3):423–427. doi: 10.1592/phco.26.3.423.
   PubMed Web of Science ®Google Scholar
• Höchtl T, Pachinger L, Unger G, et al. Antiplatelet drug induced isolated profound thrombocytopenia in interventional cardiology: a review based on individual case reports. J Thromb Thrombolysis. 2007;24(1):59–64. doi: 10.1007/s11239-006-9052-1.
   PubMed Web of Science ®Google Scholar
• Beiras-Fernandez A, Kowert A, Jiru P, et al. Acute profound thrombocytopenia after treatment with tirofiban and off-pump coronary artery bypass grafting. Ann Thorac Surg. 2009;87(2):629–631. doi: 10.1016/j.athoracsur.2008.06.040.
   PubMed Web of Science ®Google Scholar
• Sakellariou D, et al. First report of tirofiban-induced anemia (found in combination with severe thrombocytopenia). Tex Heart Inst J. 2009;36(1):55–57.
   PubMed Web of Science ®Google Scholar
• Rahman N, Jafary FH. Vanishing platelets: rapid and extreme tirofiban-induced thrombocytopenia after percutaneous coronary intervention for acute myocardial infarction. Tex Heart Inst J. 2010;37(1):109–112.
   PubMed Web of Science ®Google Scholar
• Panduranga P, Sulaiman K. Severe thrombocytopenia following tirofiban infusion. Indian J Pharmacol. 2011;43(6):726–728.
   PubMed Web of Science ®Google Scholar
• Elcioglu OC, Ozkok A, Akpınar TS, et al. Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review. Int J Hematol. 2012;96(3):370–375. doi: 10.1007/s12185-012-1133-7.
   PubMed Web of Science ®Google Scholar
• Dursunoglu D, Taskoylu O, Gür S, et al. Tirofiban-induced acute profound thrombocytopenia after primary angioplasty. Asian Cardiovasc Thorac Ann. 2013;21(1):74–76. doi: 10.1177/0218492312445142.
   PubMedGoogle Scholar
• Yurtdaş M, Yaylali YT, Aladağ N, et al. Acute serious thrombocytopenia associated with intracoronary tirofiban use for primary angioplasty. Case Rep Med. 2014;2014:190149.
   PubMedGoogle Scholar
• Li Y, Xu Q, Guo X. Thromboembolic events secondary to tirofiban-induced thrombocytopenia being treated with thrombopoietin: a case report. Exp Ther Med. 2016;12(2):1177–1180. doi: 10.3892/etm.2016.3439.
   PubMed Web of Science ®Google Scholar
• Meghrajani V, Sabharwal N, Namana V, et al. A case of hyperacute severe thrombocytopenia occurring less than 24 hours after intravenous tirofiban infusion. Case Rep Hematol. 2018;2018:4357981.
   PubMed Web of Science ®Google Scholar
• Patti R, Sinha A, Rodriguez D, et al. Severe thrombocytopenia due to intravenous tirofiban therapy. Am J Ther. 2019;26(4):e534–e537. doi: 10.1097/MJT.0000000000000756.
   PubMed Web of Science ®Google Scholar
• Liu Y-Y, Dong Q-T, Guo Y-L, et al. Tirofiban-Induced severe thrombocytopenia. Am J Ther. 2019;26(5):e659–e661. doi: 10.1097/MJT.0000000000000861.
   PubMed Web of Science ®Google Scholar
• Kabadi RA, Danelich IM, Entwistle JW, et al. Use of cangrelor as a bridge to left ventricular assist device implantation in a patient with a recent drug-eluting stent who developed acute Tirofiban-Related thrombocytopenia. Pharmacotherapy. 2019;39(4):521–525. doi: 10.1002/phar.2219.
   PubMed Web of Science ®Google Scholar
• Wang S, Sawalha K, Khan A. An unusual case of drug-induced thrombocytopenia. J Investig Med High Impact Case Rep. 2020;8:2324709620947891. doi: 10.1177/2324709620947891.
   Web of Science ®Google Scholar
• Rawala MS, Ahmed AS, Posina K, et al. Tirofiban induced thrombocytopenia: a rare but severe adverse effect. J Community Hosp Intern Med Perspect. 2020;10(2):171–173. doi: 10.1080/20009666.2020.1747783.
   PubMed Web of Science ®Google Scholar
• Gulati A, Tiwari A, Shetty V, et al. Tirofiban: a rare cause of thrombocytopenia in a patient undergoing percutaneous coronary intervention. Cureus. 2021;13(9):e18217. doi: 10.7759/cureus.18217.
   PubMed Web of Science ®Google Scholar
• Abdeladim S, Elharras M, Elouarradi A, et al. Thrombocytopenia induced by glycoprotein (GP) IIb-IIIa antagonists: about two cases. Pan Afr Med J. 2021;38:9. doi: 10.11604/pamj.2021.38.9.27215.
   PubMed Web of Science ®Google Scholar
• Ran Y, Xu H, Huo Y, et al. Acute profound thrombocytopenia within 1 hour after small doses of tirofiban. Am J Ther. 2022. doi: 10.1097/MJT.0000000000001553.
   PubMed Web of Science ®Google Scholar
• Piao B, Li T, Zhong H, et al. Acute profound thrombocytopenia induced by tirofiban in stent assisted embolization of intracranial ruptured aneurysm-a rare case report. Heliyon. 2023;9(4):e14504. doi: 10.1016/j.heliyon.2023.e14504.
   PubMed Web of Science ®Google Scholar
• The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338(21):1488–1497.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Percoco G, Barbieri D, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE trial. J Am Coll Cardiol. 2004;44(1):14–19. doi: 10.1016/j.jacc.2004.03.042.
   PubMed Web of Science ®Google Scholar
• Dunkley S, Evans S, Gaudry L, et al. Two distinct subgroups of tirofiban-induced thrombocytopenia exist due to drug dependent antibodies that cause platelet activation and increased ischaemic events. Platelets. 2005;16(8):462–468. doi: 10.1080/09537100500140141.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA. 2005;293(17):2109–2117. doi: 10.1001/jama.293.17.2109.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA. 2008;299(15):1788–1799. doi: 10.1001/jama.299.15.joc80026.
   PubMed Web of Science ®Google Scholar
• Van’t Hof AW, ten Berg J, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (on-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet. 2008;372(9638):537–546. doi: 10.1016/S0140-6736(08)61235-0.
   PubMed Web of Science ®Google Scholar
• Garbe E, Andersohn F, Bronder E, et al. Drug-induced immune thrombocytopaenia: results from the Berlin case-control surveillance study. Eur J Clin Pharmacol. 2012;68(5):821–832. doi: 10.1007/s00228-011-1184-3.
   PubMed Web of Science ®Google Scholar
• Zanaty M, Allan L, Samaniego EA, et al. Phase 1/2a trial of ISPASM. Stroke. 2021;52(12):3750–3758. doi: 10.1161/STROKEAHA.121.034578.
   PubMed Web of Science ®Google Scholar
• Huxtable LM, Tafreshi MJ, Rakkar AN. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists. Am J Cardiol. 2006;97(3):426–429. doi: 10.1016/j.amjcard.2005.08.066.
   PubMed Web of Science ®Google Scholar
• Collet J-P, Thiele H. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(20):2020–2021. doi: 10.1093/eurheartj/ehaa909.
   PubMed Web of Science ®Google Scholar
• Wang HL, Aguilera C, Knopf KB, et al. Thrombocytopenia in the intensive care unit. J Intensive Care Med. 2013;28(5):268–280. doi: 10.1177/0885066611431551.
   PubMedGoogle Scholar
• Aster RH. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest. 2005;127(2 Suppl):53s–59s. doi: 10.1378/chest.127.2_suppl.53S.
   PubMed Web of Science ®Google Scholar
• Warkentin TE. Drug-induced immune-mediated thrombocytopenia–from purpura to thrombosis. N Engl J Med. 2007;356(9):891–893. doi: 10.1056/NEJMp068309.
   PubMed Web of Science ®Google Scholar
• Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007;357(6):580–587. doi: 10.1056/NEJMra066469.
   PubMed Web of Science ®Google Scholar
• Marini I, Uzun G, Jamal K, et al. Treatment of drug-induced immune thrombocytopenias. Haematologica. 2022;107(6):1264–1277. doi: 10.3324/haematol.2021.279484.
   PubMed Web of Science ®Google Scholar
• Bougie DW, Rasmussen M, Zhu J, et al. Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of αIIb/β3 integrin. Blood. 2012;119(26):6317–6325. doi: 10.1182/blood-2012-01-406322.
   PubMed Web of Science ®Google Scholar
• McMillan R. The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol. 2007;44(4 Suppl 5):S3–s11. doi: 10.1053/j.seminhematol.2007.11.002.
   PubMed Web of Science ®Google Scholar
• Sun S, Urbanus RT, ten Cate H, et al. Platelet activation mechanisms and consequences of immune thrombocytopenia. Cells. 2021;10(12):3386. doi: 10.3390/cells10123386.
   PubMed Web of Science ®Google Scholar
• Aster RH, Curtis BR, Bougie DW. Thrombocytopenia resulting from sensitivity to GPIIb-IIIa inhibitors. Semin Thromb Hemost. 2004;30(5):569–577. doi: 10.1055/s-2004-835677.
   PubMed Web of Science ®Google Scholar
• Berkowitz SD, Sane DC, Sigmon KN, et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) study group. J Am Coll Cardiol. 1998;32(2):311–319. doi: 10.1016/s0735-1097(98)00252-6.
   PubMed Web of Science ®Google Scholar
• Abrams CS, Cines DB. Platelet glycoprotein IIb/IIIa inhibitors and thrombocytopenia: possible link between platelet activation, autoimmunity and thrombosis. Thromb Haemost. 2002;88(12):888–889. doi: 10.1055/s-0037-1613328.
   PubMedGoogle Scholar
• Chen C-Y, Lee M-Y, Lin K-D, et al. Diabetes mellitus increases severity of thrombocytopenia in dengue-infected patients. Int J Mol Sci. 2015;16(2):3820–3830. doi: 10.3390/ijms16023820.
   PubMed Web of Science ®Google Scholar
• Mondal NK, Chen Z, Trivedi JR, et al. Oxidative stress induced modulation of platelet integrin α2bβ3 expression and shedding may predict the risk of major bleeding in heart failure patients supported by continuous flow left ventricular assist devices. Thromb Res. 2017;158:140–148. doi: 10.1016/j.thromres.2017.09.006.
   PubMed Web of Science ®Google Scholar
• Mondal NK, Li T, Chen Z, et al. Mechanistic insight of platelet apoptosis leading to non-surgical bleeding among heart failure patients supported by continuous-flow left ventricular assist devices. Mol Cell Biochem. 2017;433(1–2):125–137. doi: 10.1007/s11010-017-3021-1.
   PubMed Web of Science ®Google Scholar
• Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010;121(3):357–365. doi: 10.1161/CIRCULATIONAHA.109.865352.
   PubMed Web of Science ®Google Scholar
• Fountain EM, Moses MC, Park LP, et al. Thrombocytopenia in hospitalized patients with severe clostridium difficile infection. J Thromb Thrombolysis. 2017;43(1):38–42. doi: 10.1007/s11239-016-1423-7.
   PubMed Web of Science ®Google Scholar
• Assinger A. Platelets and infection - an emerging role of platelets in viral infection. Front Immunol. 2014;5:649. doi: 10.3389/fimmu.2014.00649.
   PubMed Web of Science ®Google Scholar
• Adamo M, Ariotti S, Costa F, et al. Phosphate- or citrate-buffered tirofiban versus unfractionated heparin and its impact on thrombocytopenia and clinical outcomes in patients with acute coronary syndrome: a post hoc analysis from the PRISM trial. JACC Cardiovasc Interv. 2016;9(16):1667–1676. doi: 10.1016/j.jcin.2016.05.031.
   PubMed Web of Science ®Google Scholar
• Groves EM, et al. Incidence, predictors, and outcomes of acquired thrombocytopenia after percutaneous coronary intervention: a pooled, patient-level analysis of the CHAMPION trials (cangrelor versus standard therapy to achieve optimal management of platelet inhibition). Circ Cardiovasc Interv. 2018;11(4):e005635.
   PubMed Web of Science ®Google Scholar
• Aster RH, Curtis BR, Bougie DW, et al. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. J Thromb Haemost. 2006;4(3):678–679. doi: 10.1111/j.1538-7836.2006.01829.x.
   PubMed Web of Science ®Google Scholar
• Desai M, Lucore CL. Uneventful use of tirofiban as an adjunct to coronary stenting in a patient with a history of abciximab-associated thrombocytopenia 10 months earlier. J Invasive Cardiol. 2000;12(2):109–112.
   PubMed Web of Science ®Google Scholar
• Simon BC, Herzum M, Klisch A, et al. Acute severe thrombocytopenia after c7E3 Fab (abciximab) therapy in a patient with unstable angina and stenting of the right coronary artery. Occurrence of subacute stent thrombosis and safe readministration of the GPIIb/IIIa inhibitor tirofiban. Int J Cardiovasc Intervent. 2000;3(3):185–188. doi: 10.1080/14628840050516118.
   PubMedGoogle Scholar
• Coto H. Platelet receptor glycoprotein IIb/IIIa inhibition with eptifibatide in a patient with thrombocytopenia after treatment with abciximab. J Invasive Cardiol. 2000;12(10):528–531.
   PubMed Web of Science ®Google Scholar
• Rao J, Mascarenhas DA. Successful use of eptifibatide as an adjunct to coronary stenting in a patient with abciximab-associated acute profound thrombocytopenia. J Invasive Cardiol. 2001;13(6):471–473.
   PubMedGoogle Scholar
• Lev EI, Osende JI, Richard MF, et al. Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function. J Am Coll Cardiol. 2001;37(3):847–855. doi: 10.1016/s0735-1097(00)01181-5.
   PubMed Web of Science ®Google Scholar
• George JN, Aster RH. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program. 2009;2009(1):153–158. doi: 10.1182/asheducation-2009.1.153.
   Google Scholar